A researcher in a lab using AI to analyze Reddit posts on GLP-1 drug side effects, highlighting symptoms like menstrual changes.
A researcher in a lab using AI to analyze Reddit posts on GLP-1 drug side effects, highlighting symptoms like menstrual changes.
AI 生成的图像

AI analysis of Reddit posts highlights potential underrecognized side effects linked to GLP-1 drugs

AI 生成的图像
事实核查

Researchers at the University of Pennsylvania used artificial intelligence to analyze more than 400,000 Reddit posts about GLP-1 medications such as semaglutide and tirzepatide, identifying frequently discussed symptoms—including menstrual changes and temperature-related complaints—that may be less prominent in clinical trial reporting and drug labeling.

A study from the University of Pennsylvania School of Engineering and Applied Science, published in Nature Health in 2026, used large language models to analyze more than 400,000 Reddit posts written by nearly 70,000 users over a period of more than five years.

The researchers reported that many users described side effects commonly associated with GLP-1 drugs, particularly gastrointestinal problems. About 44% of users in the sample mentioned at least one side effect.

The analysis also flagged symptoms that the researchers said may warrant closer scrutiny, while emphasizing that the study does not establish that the medications caused the complaints described online. Nearly 4% of users who reported side effects also described reproductive symptoms, including irregular menstrual cycles, intermenstrual bleeding and heavy bleeding. Users also discussed temperature-related issues such as chills, feeling cold and hot flashes, and fatigue emerged as a frequently mentioned complaint.

The authors suggested that AI-assisted monitoring of large volumes of social media discussion could complement traditional pharmacovigilance by surfacing patient concerns more quickly, while noting that Reddit users are not representative of the broader population and that online reports can be incomplete or biased.

相关文章

Illustration of high-risk patients benefiting from GLP-1 drugs like Ozempic with reduced heart risks
AI 生成的图像

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

由 AI 报道 AI 生成的图像 事实核查

A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.

A year-long observational study in Japan suggests that people with type 2 diabetes who tend to overeat in response to tempting food cues such as sight and smell may see greater weight loss—and possibly better blood-sugar improvement—after starting GLP-1 receptor agonists, while those with primarily emotional eating patterns show less consistent links to long-term outcomes.

由 AI 报道 事实核查

Many adults with type 2 diabetes who pause GLP-1 medications such as semaglutide (Ozempic) later resume treatment, according to research scheduled for presentation at ENDO 2026 in Chicago.

A new study shows that oral GLP-1 receptor agonists can curb pleasure-driven eating in mice by acting on a brain reward circuit. The research, supported by the National Institutes of Health, examined drugs including orforglipron and danuglipron.

由 AI 报道

Women taking GLP-1 medications such as Ozempic and Wegovy showed about 30 percent lower odds of developing breast cancer in a large observational study.

Researchers at Aarhus University report that the hormone GLP-1—mimicked by drugs such as Wegovy—can be measured in the joint fluid of patients with inflammatory arthritis, but only at very low levels. The findings, published in The Lancet Rheumatology, suggest GLP-1–based medicines might eventually be studied for potential direct effects on joint inflammation, though the researchers say clinical trials are needed to show whether such treatment works.

由 AI 报道 事实核查

Semaglutide was associated with a lower rate of bone fractures and greater reductions in body mass index among adults with type 2 diabetes, according to a retrospective analysis presented at the Endocrine Society’s ENDO 2026 meeting in Chicago.

 

 

 

此网站使用 cookie

我们使用 cookie 进行分析以改进我们的网站。阅读我们的 隐私政策 以获取更多信息。
拒绝